NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: American International Biotechnology

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AIBioTech Announces Dr. Dave Li As Their New Clinical Director - American International Biotechnology, LLC (AIBioTech), Richmond VA, is proud to announce Dr. Dai (Dave) J. Li as their new Clinical Director - AIBioTech.com
AIBioTech Announces Dr. Dave Li As Their New Clinical Director

 

NewswireTODAY - /newswire/ - Richmond, VA, United States, 2015/03/19 - American International Biotechnology, LLC (AIBioTech), Richmond VA, is proud to announce Dr. Dai (Dave) J. Li as their new Clinical Director - AIBioTech.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Dr. Li will be conducting clinical trial studies by utilizing the combined approach of diagnostic testing and clinical informatics in the field of precision medicine.
“I am excited about my new roles as the Clinical Director of AIBioTech. AIBioTech is at the forefront of the movement of precision medicine with its state-of-the-art assay portfolios and robust research capabilities especially that are enabled by the powerful Next Generation DNA Sequencing technologies for pharmacogenomics testing and cancer risk assessment. I have no doubt that the integrated approach of the innovative advanced laboratory testing with biomedical informatics as exemplified by the AIBioTech’s business model will provide greater insights of human illnesses propelling the future growth of the corporation and bring substantial value to the future patient care delivery and outcomes”, stated Dr. Li.

Dr. Li obtained his MB/MD at the Sun Yat-Sen University, School of Medicine and Cancer Center in Guangzhou, China, and his MSc/PhD from the University of Texas M.D. Anderson Cancer Center in Houston, Texas. He received additional training in tumor immunology from the Department of Surgery and Organ Transplantation at the University of Texas Health Science Center in Houston, as well as in Clinical Informatics from the Department of Health Informatics at The Johns Hopkins University School of Medicine in Baltimore, Maryland.

He completed a combined residency in medical oncology and laboratory medicine at the Sun Yat-Sen University Cancer Center in Guangzhou, China. Subsequently, he did clinical fellowships in Clinical Pathology at the University of Texas Southwestern Medical Center and Parkland Memorial Hospital in Dallas, Texas, as well as at the Johns Hopkins Hospital in Baltimore, Maryland. Dr. Li’s career spans academic institutions, government and commercial operations including positions at Johns Hopkins Medical Institutions School of Medicine, Wako Chemicals, USA, Inc., the U.S. Food and Drug Administration, Wako Life Sciences and Health Diagnostic Laboratory, Inc.

Dr. Li is a physician certified by the American Medical Association (AMA) and the United States National Board of Medical Examiners holding a permanent ECFMG Certificate. He is also a certified clinical laboratory director by the College of American Pathologists (CAP) and Center for Medicare and Medicaid Services (CMS/CLIA). He is a member of many professional societies including AMA, American Society of Clinical Pathology (ASCP), American Society of Clinical Oncology (ASCO), and American College of Physician Executive (ACPE), American Medical Informatics Association (AMIA), and American Association for the Study of Liver Disease (AASLD), and Endocrine Society. Dr. Li has over twenty publications as an author or co-author in peer-reviewed medical journals, as well as book chapters on oncology drug discovery and development.

Dr. David Bostwick, CEO of AIBioTech, stated that “Dr. Li brings a great breadth of knowledge and experience to AIBioTech. His past work with the FDA, Johns Hopkins and HDL have given him a remarkably complete understanding of clinical needs in the current laboratory environment.”

About AIBioTech

AIBioTech (aibiotech.com) is a comprehensive contract research organization which provides clinical testing and research and development services to physicians and life science investigators in biotechnology and pharmaceutical companies, academic institutions, and in several different government agencies. It also operates a forensics and paternity testing division under the name Fairfax Identity Laboratories.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: American International Biotechnology

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AIBioTech Announces Dr. Dave Li As Their New Clinical Director

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
AiBioTech |
Contact: Kelley W. Randall - AIBioTech.com 
804-648-3820 krandall[.]aibiotech.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any American International Biotechnology securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From American International Biotechnology / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

BASF to Invest in its Aroma Ingredients Business by Expanding its Global Production Footprint eith New Plants in China and Germany
Otsuka Chemical and Yokogawa Electric to Launch SynCrest Inc., a Joint Venture Targeting the CRDMO Business for Middle-molecular Drugs
Ipsen, Université de Montréal and IRICoR Broaden Existing Oncology Partnership, with an Exclusive License Agreement & Two New Discovery-stage Programs
Flagship Biosciences Applauded by Frost & Sullivan for Changing Biomarker Analysis to Find Biomarkers that Aid Drug Development and Diagnostics
Cabometyx® in Combination with Nivolumab Shows Durable Survival Benefits At Over Three-years’ Follow-up in First-line Advanced Renal Cell Carcinoma
Novotech Awarded by Frost & Sullivan for Global Biotech Clinical Trials Excellence in APAC
Ipsen Receives CHMP Negative Opinion for Palovarotene as A Treatment for Fibrodysplasia Ossificans Progressiva in E.U
Ipsen Presents Positive Results from the Pivotal Phase III NAPOLI 3 Trial Evaluating An Investigational Regimen of Onivyde®
SCHOTT Opens First Facility in U.S. to Increase Capabilities and Capacity for Development and Manufacturing of Diagnostics and Life Sciences Products
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease with Treatments for Several Pediatric Liver Diseases
Biognosys and Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma and Biomarker Customers
Ipsen Demonstrates Commitment to Innovation in Neuroscience At 12th World Congress for Neurorehabilitation (WCNR)
BASF Pharma Solutions Excipient Accepted into FDA Pilot Program for Novel Excipients
Digital Technologies Drive Growth Across the Biomanufacturing Value Chain Finds Frost & Sullivan
DSM Starts Construction of Large Scale Production Facility for its Novel Methane-reducing Feed Additive for Ruminants, Bovaer® in Dalry, Scotland

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2005-2023 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)